Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Apr;33(4):519–521. doi: 10.1128/aac.33.4.519

Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.

G W Kaatz 1, S M Seo 1, S L Barriere 1, L M Albrecht 1, M J Rybak 1
PMCID: PMC172471  PMID: 2499251

Abstract

The efficacy of fleroxacin versus that of vancomycin was assessed by using the rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Animals were treated with fleroxacin (30 mg/kg of body weight every 8 h) or vancomycin (17.5 mg/kg every 6 h) for 4 days. These antimicrobial agents were equally effective in clearing bacteremia, reducing bacterial counts in vegetations and tissues, and curing endocarditis. However, resistance to fleroxacin at fivefold the MIC arose in the test strain of S. aureus in 8% of animals that received the drug. We conclude that fleroxacin is as efficacious as vancomycin in this model of a serious systemic S. aureus infection, but modest resistance to fleroxacin may develop during therapy.

Full text

PDF
519

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barriere S. L., Kaatz G. W., Schaberg D. R., Fekety R. Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. Antimicrob Agents Chemother. 1987 Jul;31(7):1075–1078. doi: 10.1128/aac.31.7.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chin N. X., Brittain D. C., Neu H. C. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother. 1986 Apr;29(4):675–680. doi: 10.1128/aac.29.4.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gilbert M., Boscia J. A., Kobasa W. D., Kaye D. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1986 Mar;29(3):461–463. doi: 10.1128/aac.29.3.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kaatz G. W., Barriere S. L., Schaberg D. R., Fekety R. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1987 Apr;31(4):527–530. doi: 10.1128/aac.31.4.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kaatz G. W., Barriere S. L., Schaberg D. R., Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother. 1987 Nov;20(5):753–758. doi: 10.1093/jac/20.5.753. [DOI] [PubMed] [Google Scholar]
  6. Leclercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988 Jul 21;319(3):157–161. doi: 10.1056/NEJM198807213190307. [DOI] [PubMed] [Google Scholar]
  7. Schwalbe R. S., Stapleton J. T., Gilligan P. H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 1987 Apr 9;316(15):927–931. doi: 10.1056/NEJM198704093161507. [DOI] [PubMed] [Google Scholar]
  8. Schwenzer K. S., Wang C. H., Anhalt J. P. Automated fluorescence polarization immunoassay for monitoring vancomycin. Ther Drug Monit. 1983;5(3):341–345. doi: 10.1097/00007691-198309000-00017. [DOI] [PubMed] [Google Scholar]
  9. Stratton C. W., Reller L. B. Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent. J Infect Dis. 1977 Aug;136(2):187–195. doi: 10.1093/infdis/136.2.187. [DOI] [PubMed] [Google Scholar]
  10. Sullam P. M., Täuber M. G., Hackbarth C. J., Chambers H. F., Scott K. G., Sande M. A. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1985 May;27(5):685–687. doi: 10.1128/aac.27.5.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Weidekamm E., Portmann R., Suter K., Partos C., Dell D., Lücker P. W. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob Agents Chemother. 1987 Dec;31(12):1909–1914. doi: 10.1128/aac.31.12.1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES